Low-dose dexamethasone suppression is considered to be the most accurate test for diagnosing subclinical hypercortisolism (1±3). The recommended cut-off point for excluding the presence of Cushing's syndrome is a morning plasma cortisol concentration of less than 50 nmol/l after 1 mg dexamethasone. We read, with interest, the article by Valli et al. (4), who assessed the value of endocrine testing, as opposed to radiocholesterol scintigraphy, in diagnosing subclinical cortisol hypersecretion in a series of incidentally discovered adrenocortical adenomas. Patients showing unilateral uptake by their adrenal mass at scintigraphy had signi®cantly lower adrenocorticotrophin levels, higher midnight levels of plasma cortisol, abnormalities of the cortisol diurnal rhythm, and higher cortisol concentrations after overnight administration of 1 mg and (i.v.) 4 mg dexamethasone than did patients with bilateral uptake. The sensitivity of the overnight 1 mg dexamethasone suppression test improved to 100% when the cut-off point for the morning plasma cortisol level was set at 60 nmol/l, rather than the classical value of 138 nmol/l.
Low-dose dexamethasone suppression is considered to be the most accurate test for diagnosing subclinical hypercortisolism (1±3). The recommended cut-off point for excluding the presence of Cushing's syndrome is a morning plasma cortisol concentration of less than 50 nmol/l after 1 mg dexamethasone. We read, with interest, the article by Valli et al. (4) , who assessed the value of endocrine testing, as opposed to radiocholesterol scintigraphy, in diagnosing subclinical cortisol hypersecretion in a series of incidentally discovered adrenocortical adenomas. Patients showing unilateral uptake by their adrenal mass at scintigraphy had signi®cantly lower adrenocorticotrophin levels, higher midnight levels of plasma cortisol, abnormalities of the cortisol diurnal rhythm, and higher cortisol concentrations after overnight administration of 1 mg and (i.v.) 4 mg dexamethasone than did patients with bilateral uptake. The sensitivity of the overnight 1 mg dexamethasone suppression test improved to 100% when the cut-off point for the morning plasma cortisol level was set at 60 nmol/l, rather than the classical value of 138 nmol/l.
In our population of patients with adrenal incidentaloma (5), we re-evaluated the accuracy of the 1 mg overnight dexamethasone suppression test by comparing the new cut-off point for plasma cortisol (50 nmol/l at 0800 h the following day) with adrenocortical scintigraphy. Out of 284 consecutive patients, 83 with unilateral scintigraphic uptake and histological diagnosis of adrenocortical adenoma were selected. Adrenal scintiscans were performed using 11±14 MBq [
75 Se]-Selenio-6a-methyl-19norcholesterol (Scintadren; Amersham, Buckinghamshire, UK). Images were acquired at 72±120 h following tracer injection. Scintigraphic evaluation demonstrated various patterns of uptake: (i) exclusive uptake by the tumor without visualization of the contralateral gland (36 subjects); (ii) prevalent uptake by the tumor with visualization of the contralateral gland (28 subjects); (iii) bilateral symmetrical uptake (19 subjects). The results of the overnight dexamethasone suppression test demonstrated a strong association with scintigraphic uptake, and a continuous spectrum in adrenal autonomy (Table 1) . Moreover, all patients with plasma cortisol levels above 138 nmol/l after dexamethasone showed exclusive uptake at scintigraphy. With a plasma cortisol cut-off point of 138 nmol/l, the sensitivity and speci®city of the overnight dexamethasone suppression test for identifying subclinical cortisol-secreting adenomas (exclusive uptake) were 44% and 100% respectively. With a lowering of the cut-off point to 50 nmol/l, the sensitivity improved to 75%, but the speci®city fell to 72%. Although the sensitivity of the test was lower in our experience, our data are in agreement with those of Valli et al. (4) , con®rming the usefulness of 1 mg overnight dexamethasone suppression, with revised criteria, as a screening test for subclinical hypercortisolism in patients with adrenal incidentaloma. 
